US 12,409,214 B2
Immunogenic antigens
Jeffrey D. Fischer, Washington, DC (US); Clara J. Sei, Germantown, MD (US); Luke T. Daum, San Antonio, TX (US); and Gerald W. Fischer, Bethesda, MD (US)
Assigned to Longhorn Vaccines and Diagnostics, LLC, Bethesda, MD (US)
Filed by Longhorn Vaccines and Diagnostics, LLC, Bethesda, MD (US)
Filed on Oct. 20, 2021, as Appl. No. 17/506,254.
Claims priority of provisional application 63/246,360, filed on Sep. 21, 2021.
Claims priority of provisional application 63/094,472, filed on Oct. 21, 2020.
Claims priority of provisional application 63/094,116, filed on Oct. 20, 2020.
Prior Publication US 2022/0296696 A1, Sep. 22, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 39/02 (2006.01); A61K 39/04 (2006.01); A61K 39/09 (2006.01); A61K 39/095 (2006.01); A61K 39/102 (2006.01); A61K 39/116 (2006.01); A61K 39/385 (2006.01); A61K 47/64 (2017.01); A61P 31/16 (2006.01); A61P 37/04 (2006.01); A61K 39/00 (2006.01); A61K 39/145 (2006.01)
CPC A61K 39/116 (2013.01) [A61K 39/04 (2013.01); A61K 39/092 (2013.01); A61K 39/095 (2013.01); A61K 39/102 (2013.01); A61K 39/385 (2013.01); A61K 47/6415 (2017.08); A61K 47/646 (2017.08); A61P 31/16 (2018.01); A61P 37/04 (2018.01); A61K 39/145 (2013.01); A61K 2039/5252 (2013.01); A61K 2039/5254 (2013.01); A61K 2039/53 (2013.01); A61K 2039/543 (2013.01); A61K 2039/545 (2013.01); A61K 2039/55555 (2013.01); A61K 2039/55566 (2013.01); A61K 2039/55572 (2013.01); A61K 2039/575 (2013.01); A61K 2039/6037 (2013.01); A61K 2039/6043 (2013.01); A61K 2039/6068 (2013.01); A61K 2039/70 (2013.01)] 28 Claims
 
1. An immunogenic antigen comprised of:
a contiguous peptide containing one or more bacterial epitopes and one or more influenza epitopes, and
a T cell stimulating epitope and/or an adjuvant,
wherein the one or more bacterial epitopes are selected from the group consisting of cell wall epitopes of Mycobacteria, and the one or more influenza epitopes are selected from the group consisting of epitopes of hemagglutinin (HA), neuraminidase (NA) and matrix proteins of influenza virus, wherein the contiguous peptide comprises the sequences of one or more of SEQ ID NOs. 1-20 and one or more of SEQ ID NOs. 25-28, or the sequence of one or more of SEQ ID NOs. 9-17 and 20-23.